These letters explain what medicine suppliers need to consider in the period leading up to March 2019.
The first letter is aimed at medicine suppliers from the EU and EEA. It includes information on:
- EU and EEA pharmaceutical companies that supply prescription-only medicines and pharmacy medicines to the UK
- an update on medicine supply preparations for a potential no-deal Brexit
The second letter is aimed at UK medicines manufacturers. It gives an update on medicine supply preparations for a potential no-deal Brexit for UK medicines manufacturers who may currently be using the short straits crossings into Dover and Folkestone to import raw materials into the UK.